يعرض 201 - 220 نتائج من 34,485 نتيجة بحث عن '(((( 50 ((mg decrease) OR (we decrease)) ) OR ( a non decrease ))) OR ( 50 a decrease ))', وقت الاستعلام: 0.82s تنقيح النتائج
  1. 201

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  2. 202

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  3. 203

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  4. 204

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  5. 205

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  6. 206

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx حسب Qiao Liu (346535)

    منشور في 2021
    "…<p>Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. …"
  7. 207
  8. 208
  9. 209
  10. 210

    Video_1_Why Does Child Mortality Decrease With Age? Modeling the Age-Associated Decrease in Mortality Rate Using WHO Metadata From 25 Countries.MP4 حسب Josef Dolejs (5534258)

    منشور في 2021
    "…<p>Background: Our previous study analyzed the age trajectory of mortality (ATM) in 14 European countries, while this study aimed at investigating ATM in other continents and in countries with a higher level of mortality. Data from 11 Non-European countries were used.…"
  11. 211

    Data_Sheet_2_Why Does Child Mortality Decrease With Age? Modeling the Age-Associated Decrease in Mortality Rate Using WHO Metadata From 25 Countries.zip حسب Josef Dolejs (5534258)

    منشور في 2021
    "…<p>Background: Our previous study analyzed the age trajectory of mortality (ATM) in 14 European countries, while this study aimed at investigating ATM in other continents and in countries with a higher level of mortality. Data from 11 Non-European countries were used.…"
  12. 212

    Video_2_Why Does Child Mortality Decrease With Age? Modeling the Age-Associated Decrease in Mortality Rate Using WHO Metadata From 25 Countries.MP4 حسب Josef Dolejs (5534258)

    منشور في 2021
    "…<p>Background: Our previous study analyzed the age trajectory of mortality (ATM) in 14 European countries, while this study aimed at investigating ATM in other continents and in countries with a higher level of mortality. Data from 11 Non-European countries were used.…"
  13. 213

    SUI-sEVs decreased the migration ability of primary cultured fibroblasts. حسب Xiaoyan Sun (28501)

    منشور في 2021
    "…SUI-sEVs significant decreased the migration ability of primary cultured fibroblasts at 48h when compared to the cells in control group and treated with the non SUI-sEVs. …"
  14. 214

    Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? حسب Isa Sincer (7234577)

    منشور في 2019
    "…<div><p>Abstract Background: Coronary artery fistula (CAF) is an abnormal connection that links a coronary artery to a cardiac chamber or another major blood vessel. …"
  15. 215

    Table1_Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy.docx حسب Anselm A. Derda (5866220)

    منشور في 2024
    "…</p>Results<p>16 patients discontinued their afterload-reducing drugs, resulting in a significant decrease in median LVOT gradient from 86.5 [60.5–109.3] mmHg to 61.5 [28.3–97.50] mmHg (p = 0.0004). …"
  16. 216

    Table1_Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy.docx حسب Anselm A. Derda (5866220)

    منشور في 2024
    "…</p>Results<p>16 patients discontinued their afterload-reducing drugs, resulting in a significant decrease in median LVOT gradient from 86.5 [60.5–109.3] mmHg to 61.5 [28.3–97.50] mmHg (p = 0.0004). …"
  17. 217
  18. 218

    Table_1_Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis.doc حسب Guannan Wang (2209297)

    منشور في 2020
    "…A history of hay fever was associated with a decreased risk of pancreatic cancer (OR, 0.57; 95% CI, 0.50–0.64, P < 0.00001) through fixed effect model.…"
  19. 219
  20. 220